TACCHETTI, PAOLA
TACCHETTI, PAOLA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
2007-01-01 Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S.
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
2016-01-01 Zamagni, E; Nanni, C; Gay, F; Pezzi, A; Patriarca, F; Bellò, M; Rambaldi, I; Tacchetti, P; Hillengass, J; Gamberi, B; Pantani, L; Magarotto, V; Versari, A; Offidani, M; Zannetti, B; Carobolante, F; Balma, M; Musto, P; Rensi, M; Mancuso, K; Dimitrakopoulou-Strauss, A; Chauviè, S; Rocchi, Serena; Fard, N; Marzocchi, G; Storto, G; Ghedini, P; Palumbo, A; Fanti, S; Cavo, M
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
2007-01-01 Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M.
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma
2020-01-01 Poletti, Andrea; Solli, Vincenza; Martello, Marina; Borsi, Enrica; Pantani, Lucia; Lakpo, Agboyi; Armuzzi, Silvia; Cifarelli, Luca Nunzio; Zamagni, Elena; Tacchetti, Paola; Rocchi, Serena; Mancuso, Katia; Rizzello, Ilaria; Marzocchi, Giulia; Testoni, Nicoletta; Dozza, Luca; Petrucci, Maria Teresa; Liberati, Anna Marina; Rossi, Giuseppe; Boccadoro, Mario; Cavo, Michele; Terragna, Carolina
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
2018-01-01 Zamagni, Elena; Tacchetti, Paola; Pantani, Lucia; Cavo, Michele
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
2011-01-01 Palumbo A.; Cavo M.; Bringhen S.; Zamagni E.; Romano A.; Patriarca F.; Rossi D.; Gentilini F.; Crippa C.; Galli M.; Nozzoli C.; Ria R.; Marasca R.; Montefusco V.; Baldini L.; Elice F.; Callea V.; Pulini S.; Carella A.M.; Zambello R.; Benevolo G.; Magarotto V.; Tacchetti P.; Pescosta N.; Cellini C.; Polloni C.; Evangelista A.; Caravita T.; Morabito F.; Offidani M.; Tosi P.; Boccadoro M.
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
2014-01-01 Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Brioli;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
2010-01-01 Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study
2020-01-01 Tacchetti P.; Pantani L.; Patriarca F.; Petrucci M.T.; Zamagni E.; Dozza L.; Galli M.; Di Raimondo F.; Crippa C.; Boccadoro M.; Barbato S.; Tosi P.; Narni F.; Montefusco V.; Testoni N.; Spadano A.; Terragna C.; Pescosta N.; Marzocchi G.; Cellini C.; Galieni P.; Ronconi S.; Gobbi M.; Catalano L.; Lazzaro A.; De Sabbata G.; Cangialosi C.; Ciambelli F.; Musto P.; Elice F.; Cavo M.; Fanin R.; Foa' R.; Rambaldi A.; Rossi G.; Leoni P.; Corradini P.; Torelli G.; Fioritoni G.; Cortelazzo S.; Lambertenghi Deliliers G.; La Nasa G.; Zaccaria A.; De Fabritiis P.; Cascavilla N.; Bosi A.; Semenzato G.; Gugliotta L.; Gherlinzoni F.; Angelucci E.; Martelli M.F.; Petti M.C.; Leone G.; Carella A.M.; Ciceri F.; Santoro A.; Ferrara F.; Nobile F.; D'Arco A.M.; Levis A.; Guardigni L.; Gallamini A.; Fattori P.P.; Morandi S.; Amadori D.; Rotoli B.; Mirto S.; Paladini G.; Mozzana R.; Pinotti G.; Rodeghiero F.; Cantore N.; Pavone V.; Pogliani E.M.; Liberati A.M.; Majolino I.; Amadori S.; Lauria F.; Aglietta M.; Quarta G.; Storti S.; Morabito F.; Capalbo S.F.; Gianni A.M.; Mettivier V.; Rizzoli V.; Bernasconi C.; Visani G.; Pizzuti M.; La Verde G.; Avvisati G.; Longinotti M.; Gallo E.; Dammacco F.; Russo D.; Bacigalupo A.; Musolino C.
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
2014-01-01 Tacchetti, P.; Terragna, C.; Galli, M.; Zamagni, E.; Petrucci, M. T.; Pezzi, A.; Montefusco, V.; Martello, M.; Tosi, P.; Baldini, L.; Peccatori, J.; Ruggieri, M.; Pantani, L.; Lazzaro, A.; Elice, F.; Rocchi, S.; Gozzetti, A.; Cavaletti, G.; Palumbo, A.; Cavo, M.
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
2015-01-01 Zannetti, Beatrice Anna; Zamagni, Elena; Santostefano, Marisa; De Sanctis, Lucia Barbara; Tacchetti, Paola; Mancini, Elena; Pantani, Lucia; Brioli, Annamaria; Rizzo, Raffaella; Mancuso, Katia; Rocchi, Serena; Pezzi, Annalisa; Borsi, Enrica; Terragna, Carolina; Marzocchi, Giulia; Santoro, Antonio; Cavo, Michele
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
2013-01-01 P. Sonneveld;H. Goldschmidt;L. Rosinol;J. Blade;J. J. Lahuerta;M. Cavo;P. Tacchetti;E. Zamagni;M. Attal;H. M. Lokhorst;A. Desai;A. Cakana;K. Liu;H. van de Velde;D.-L. Esseltine;P. Moreau
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
2015-01-01 Cavo, M; Pantani, L; Pezzi, A; Petrucci, M T; Patriarca, F; Di Raimondo, F; Marzocchi, G; Galli, M; Montefusco, V; Zamagni, E; Gamberi, B; Tacchetti, P; Brioli, A; Palumbo, A; Sonneveld, P
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.
2014-01-01 Bringhen, S; Petrucci, Mt; Larocca, A; Conticello, C; Rossi, D; Magarotto, V; Musto, P; Boccadifuoco, L; Offidani, M; Omedé, P; Gentilini, F; Ciccone, G; Benevolo, G; Genuardi, M; Montefusco, V; Oliva, S; Caravita, T; Tacchetti, P; Boccadoro, M; Sonneveld, P; Palumbo, A
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS
2010-01-01 Terragna C.; Remondini D.; Martinelli G.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Brioli A.; Ceccolini M.; Testoni N.; Marzocchi G.; Castellani G.; Durante S.; Di Raimondo F.; Patriarca F.; Catalano L.; Masini L.; Ledda A.; Angelucci E.; Galieni P.; Gozzetti A.; Baccarani M.; Cavo M.
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
2022-01-01 Martello M.; Poletti A.; Borsi E.; Solli V.; Dozza L.; Barbato S.; Zamagni E.; Tacchetti P.; Pantani L.; Mancuso K.; Vigliotta I.; Rizzello I.; Rocchi S.; Armuzzi S.; Testoni N.; Marzocchi G.; Martinelli G.; Cavo M.; Terragna C.
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
2006-01-01 Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M.
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation
2013-01-01 Carolina Terragna;Matteo Renzulli;Daniel Remondini;Enrico Tagliafico;Francesco Di Raimondo;Francesca Patriarca;Giovanni Martinelli;Enrica Roncaglia;Luciano Masini;Patrizia Tosi;Elena Zamagni;Paola Tacchetti;Antonio Ledda;Annamaria Brioli;Emanuele Angelucci;Nicoletta Testoni;Giulia Marzocchi;Piero Galieni;Alessandro Gozzetti;Marina Martello;Flores Dico;Katia Mancuso;Michele Cavo
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
2016-01-01 Pantani, L; Brioli, A; Tacchetti, P; Zannetti, B A; Mancuso, K; Rocchi, Serena; Martello, M; Rizzello, I; Terragna, C; Zamagni, E; Cavo, M
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
2014-01-01 Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. | Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosi...ni V; Montini GC; Al-Nahhas A; Franchi R; Fanti S. | 2007-01-01 | WORLD JOURNAL OF SURGICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease | Zamagni, E; Nanni, C; Gay, F; Pezzi, A; Patriarca, F; Bellò, M; Rambaldi, I; Tacchetti, P; Hillen...gass, J; Gamberi, B; Pantani, L; Magarotto, V; Versari, A; Offidani, M; Zannetti, B; Carobolante, F; Balma, M; Musto, P; Rensi, M; Mancuso, K; Dimitrakopoulou-Strauss, A; Chauviè, S; Rocchi, Serena; Fard, N; Marzocchi, G; Storto, G; Ghedini, P; Palumbo, A; Fanti, S; Cavo, M | 2016-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | zamagni.pdf |
| A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. | Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini... D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma | Poletti, Andrea; Solli, Vincenza; Martello, Marina; Borsi, Enrica; Pantani, Lucia; Lakpo, Agboyi;... Armuzzi, Silvia; Cifarelli, Luca Nunzio; Zamagni, Elena; Tacchetti, Paola; Rocchi, Serena; Mancuso, Katia; Rizzello, Ilaria; Marzocchi, Giulia; Testoni, Nicoletta; Dozza, Luca; Petrucci, Maria Teresa; Liberati, Anna Marina; Rossi, Giuseppe; Boccadoro, Mario; Cavo, Michele; Terragna, Carolina | 2020-01-01 | - | - | 4.01 Contributo in Atti di convegno | - |
| Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy | Zamagni, Elena; Tacchetti, Paola; Pantani, Lucia; Cavo, Michele | 2018-01-01 | EXPERT REVIEW OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. | Palumbo A.; Cavo M.; Bringhen S.; Zamagni E.; Romano A.; Patriarca F.; Rossi D.; Gentilini F.; Cr...ippa C.; Galli M.; Nozzoli C.; Ria R.; Marasca R.; Montefusco V.; Baldini L.; Elice F.; Callea V.; Pulini S.; Carella A.M.; Zambello R.; Benevolo G.; Magarotto V.; Tacchetti P.; Pescosta N.; Cellini C.; Polloni C.; Evangelista A.; Caravita T.; Morabito F.; Offidani M.; Tosi P.; Boccadoro M. | 2011-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes | Lucia Pantani;Elena Zamagni;Beatrice Anna Zannetti;Annalisa Pezzi;Paola Tacchetti;Annamaria Briol...i;Katia Mancuso;Giulia Perrone;Serena Rocchi;Patrizia Tosi;Michele Cavo | 2014-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. | Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamag...ni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M | 2010-01-01 | THE LANCET | - | 1.01 Articolo in rivista | - |
| Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study | Tacchetti P.; Pantani L.; Patriarca F.; Petrucci M.T.; Zamagni E.; Dozza L.; Galli M.; Di Raimond...o F.; Crippa C.; Boccadoro M.; Barbato S.; Tosi P.; Narni F.; Montefusco V.; Testoni N.; Spadano A.; Terragna C.; Pescosta N.; Marzocchi G.; Cellini C.; Galieni P.; Ronconi S.; Gobbi M.; Catalano L.; Lazzaro A.; De Sabbata G.; Cangialosi C.; Ciambelli F.; Musto P.; Elice F.; Cavo M.; Fanin R.; Foa' R.; Rambaldi A.; Rossi G.; Leoni P.; Corradini P.; Torelli G.; Fioritoni G.; Cortelazzo S.; Lambertenghi Deliliers G.; La Nasa G.; Zaccaria A.; De Fabritiis P.; Cascavilla N.; Bosi A.; Semenzato G.; Gugliotta L.; Gherlinzoni F.; Angelucci E.; Martelli M.F.; Petti M.C.; Leone G.; Carella A.M.; Ciceri F.; Santoro A.; Ferrara F.; Nobile F.; D'Arco A.M.; Levis A.; Guardigni L.; Gallamini A.; Fattori P.P.; Morandi S.; Amadori D.; Rotoli B.; Mirto S.; Paladini G.; Mozzana R.; Pinotti G.; Rodeghiero F.; Cantore N.; Pavone V.; Pogliani E.M.; Liberati A.M.; Majolino I.; Amadori S.; Lauria F.; Aglietta M.; Quarta G.; Storti S.; Morabito F.; Capalbo S.F.; Gianni A.M.; Mettivier V.; Rizzoli V.; Bernasconi C.; Visani G.; Pizzuti M.; La Verde G.; Avvisati G.; Longinotti M.; Gallo E.; Dammacco F.; Russo D.; Bacigalupo A.; Musolino C. | 2020-01-01 | THE LANCET. HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. | Tacchetti, P.; Terragna, C.; Galli, M.; Zamagni, E.; Petrucci, M. T.; Pezzi, A.; Montefusco, V.; ...Martello, M.; Tosi, P.; Baldini, L.; Peccatori, J.; Ruggieri, M.; Pantani, L.; Lazzaro, A.; Elice, F.; Rocchi, S.; Gozzetti, A.; Cavaletti, G.; Palumbo, A.; Cavo, M. | 2014-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment | Zannetti, Beatrice Anna; Zamagni, Elena; Santostefano, Marisa; De Sanctis, Lucia Barbara; Tacchet...ti, Paola; Mancini, Elena; Pantani, Lucia; Brioli, Annamaria; Rizzo, Raffaella; Mancuso, Katia; Rocchi, Serena; Pezzi, Annalisa; Borsi, Enrica; Terragna, Carolina; Marzocchi, Giulia; Santoro, Antonio; Cavo, Michele | 2015-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials | P. Sonneveld;H. Goldschmidt;L. Rosinol;J. Blade;J. J. Lahuerta;M. Cavo;P. Tacchetti;E. Zamagni;M.... Attal;H. M. Lokhorst;A. Desai;A. Cakana;K. Liu;H. van de Velde;D.-L. Esseltine;P. Moreau | 2013-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma | Cavo, M; Pantani, L; Pezzi, A; Petrucci, M T; Patriarca, F; Di Raimondo, F; Marzocchi, G; Galli, ...M; Montefusco, V; Zamagni, E; Gamberi, B; Tacchetti, P; Brioli, A; Palumbo, A; Sonneveld, P | 2015-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. | Bringhen, S; Petrucci, Mt; Larocca, A; Conticello, C; Rossi, D; Magarotto, V; Musto, P; Boccadifu...oco, L; Offidani, M; Omedé, P; Gentilini, F; Ciccone, G; Benevolo, G; Genuardi, M; Montefusco, V; Oliva, S; Caravita, T; Tacchetti, P; Boccadoro, M; Sonneveld, P; Palumbo, A | 2014-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS | Terragna C.; Remondini D.; Martinelli G.; Tosi P.; Zamagni E.; Tacchetti P.; Perrone G.; Brioli A....; Ceccolini M.; Testoni N.; Marzocchi G.; Castellani G.; Durante S.; Di Raimondo F.; Patriarca F.; Catalano L.; Masini L.; Ledda A.; Angelucci E.; Galieni P.; Gozzetti A.; Baccarani M.; Cavo M. | 2010-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma | Martello M.; Poletti A.; Borsi E.; Solli V.; Dozza L.; Barbato S.; Zamagni E.; Tacchetti P.; Pant...ani L.; Mancuso K.; Vigliotta I.; Rizzello I.; Rocchi S.; Armuzzi S.; Testoni N.; Marzocchi G.; Martinelli G.; Cavo M.; Terragna C. | 2022-01-01 | BLOOD CANCER JOURNAL | - | 1.01 Articolo in rivista | s41408-022-00610-y.pdf; 41408_2022_610_MOESM1_ESM (1).docx |
| Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. | Tosi P; Zamagni E; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Baccarani M; Cavo M. | 2006-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation | Carolina Terragna;Matteo Renzulli;Daniel Remondini;Enrico Tagliafico;Francesco Di Raimondo;France...sca Patriarca;Giovanni Martinelli;Enrica Roncaglia;Luciano Masini;Patrizia Tosi;Elena Zamagni;Paola Tacchetti;Antonio Ledda;Annamaria Brioli;Emanuele Angelucci;Nicoletta Testoni;Giulia Marzocchi;Piero Galieni;Alessandro Gozzetti;Marina Martello;Flores Dico;Katia Mancuso;Michele Cavo | 2013-01-01 | ANNALS OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma | Pantani, L; Brioli, A; Tacchetti, P; Zannetti, B A; Mancuso, K; Rocchi, Serena; Martello, M; Rizz...ello, I; Terragna, C; Zamagni, E; Cavo, M | 2016-01-01 | EXPERT REVIEW OF HEMATOLOGY | - | 1.01 Articolo in rivista | pantaniexpert.pdf |
| Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. | Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G. | 2014-01-01 | CUTANEOUS AND OCULAR TOXICOLOGY | - | 1.01 Articolo in rivista | - |